Amicus Therapeutics, Inc. (DELISTED) (FOLD:DL)
14.49
0.00 (0.00%)
USD |
NASDAQ |
May 07, 16:00
Amicus Therapeutics Enterprise Value : 4.699B for May 7, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2026 | 4.699B |
| May 06, 2026 | 4.699B |
| May 05, 2026 | 4.699B |
| May 04, 2026 | 4.699B |
| May 01, 2026 | 4.699B |
| April 30, 2026 | 4.699B |
| April 29, 2026 | 4.699B |
| April 28, 2026 | 4.699B |
| April 27, 2026 | 4.699B |
| April 24, 2026 | 4.699B |
| April 23, 2026 | 4.689B |
| April 22, 2026 | 4.689B |
| April 21, 2026 | 4.689B |
| April 20, 2026 | 4.689B |
| April 17, 2026 | 4.689B |
| April 16, 2026 | 4.686B |
| April 15, 2026 | 4.689B |
| April 14, 2026 | 4.689B |
| April 13, 2026 | 4.689B |
| April 10, 2026 | 4.689B |
| April 09, 2026 | 4.692B |
| April 08, 2026 | 4.689B |
| April 07, 2026 | 4.692B |
| April 06, 2026 | 4.686B |
| April 02, 2026 | 4.683B |
| Date | Value |
|---|---|
| April 01, 2026 | 4.683B |
| March 31, 2026 | 4.689B |
| March 30, 2026 | 4.680B |
| March 27, 2026 | 4.674B |
| March 26, 2026 | 4.680B |
| March 25, 2026 | 4.680B |
| March 24, 2026 | 4.674B |
| March 23, 2026 | 4.677B |
| March 20, 2026 | 4.680B |
| March 19, 2026 | 4.664B |
| March 18, 2026 | 4.661B |
| March 17, 2026 | 4.661B |
| March 16, 2026 | 4.661B |
| March 13, 2026 | 4.661B |
| March 12, 2026 | 4.661B |
| March 11, 2026 | 4.661B |
| March 10, 2026 | 4.658B |
| March 09, 2026 | 4.661B |
| March 06, 2026 | 4.652B |
| March 05, 2026 | 4.648B |
| March 04, 2026 | 4.648B |
| March 03, 2026 | 4.652B |
| March 02, 2026 | 4.658B |
| February 27, 2026 | 4.661B |
| February 26, 2026 | 4.648B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 16.04B |
| Insmed, Inc. | 26.74B |
| Ligand Pharmaceuticals, Inc. | 5.508B |
| PTC Therapeutics, Inc. | 4.524B |
| Establishment Labs Holdings, Inc. | 2.351B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.69M |
| Revenue (Quarterly) | 185.21M |
| Total Expenses (Quarterly) | 183.52M |
| EPS Diluted (Quarterly) | 0.0054 |
| Gross Profit Margin (Quarterly) | 84.64% |
| Profit Margin (Quarterly) | 0.91% |
| Earnings Yield | -0.61% |
| Operating Earnings Yield | 0.77% |
| Normalized Earnings Yield | -0.5845 |